Ablative radiotherapy for liver tumors using stereotactic MRI-guidance: A prospective phase I trial

•SBRT using MR-Co is a safe and feasible option for treatment of liver tumors with ablative doses.•2-year LC with MRgRT is comparable to prior series using a conventional CT-guided linear accelerator.•A difference in LC between number of lesions (single vs. multiple) and BED (< or ≥100 Gy) was ob...

Full description

Saved in:
Bibliographic Details
Published in:Radiotherapy and oncology 2022-05, Vol.170, p.14-20
Main Authors: van Dams, Ritchell, Wu, Trudy C., Kishan, Amar U., Raldow, Ann C., Chu, Fang-I, Hernandez, Jackie, Cao, Minsong, Lamb, James M., Mikaeilian, Argin, Low, Daniel A., Steinberg, Michael L., Lee, Percy
Format: Article
Language:English
Subjects:
Ablative radiotherapy
Clinical trial
Liver tumors
MR-guided
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•SBRT using MR-Co is a safe and feasible option for treatment of liver tumors with ablative doses.•2-year LC with MRgRT is comparable to prior series using a conventional CT-guided linear accelerator.•A difference in LC between number of lesions (single vs. multiple) and BED (< or ≥100 Gy) was observed.•MR-guided SBRT is very well tolerated without any acute grade 3 toxicities.•V35Gy 1000 cc or >800 cc of normal liver receiving
ISSN:0167-8140
1879-0887
DOI:10.1016/j.radonc.2021.06.005